Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.22.2
Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Organization And Summary Of Significant Accounting Policies [Line Items]        
Cash, cash equivalents, and marketable securities $ 104.4   $ 104.4  
ASU No. 2021-10        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true   true  
Change in Accounting Principle, Accounting Standards Update, Adoption Date Jan. 01, 2022   Jan. 01, 2022  
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true   true  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Vertex Pharmaceuticals Inc        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of total revenues 0.00% 2.00% 0.00% 13.00%
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Takeda Pharmaceuticals Inc        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of total revenues 0.00% 85.00% 20.00% 72.00%
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Bristol Myers Squibb        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of total revenues 100.00% 13.00% 80.00% 16.00%
Other Assets        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Restricted cash $ 2.7   $ 2.7